TESAMORELIN CLINICAL STUDIES
Tesamorelin Clinical Trials: What the Research Shows
How the studies were designed, and what they actually measured
Tesamorelin clinical trials are among the more thoroughly documented in this catalog, because tesamorelin went through the formal trial process that supported an FDA approval. This page focuses on the studies themselves — their design, populations, and limits. For the separate question of legal approval, see our companion page on tesamorelin's regulatory status.
The Pivotal Trials
The approval was supported by two multicenter, randomized, double-blind, placebo-controlled studies in adults with HIV, lipodystrophy, and excess abdominal fat — together enrolling more than 800 participants. After 26 weeks, the average reduction in visceral adipose tissue was approximately 18% in one tesamorelin group (versus a 2% increase with placebo) and about 14% in the second. Overall body weight changed relatively little — itself an important finding.
Source: FDA prescribing information for EGRIFTA WR.
Fatty Liver Study
A separate randomized trial studied tesamorelin in 61 people with HIV and nonalcoholic fatty liver disease, reporting a roughly 37% relative reduction in liver fat versus placebo. It was a small study in a specific population, and fatty liver is not an approved use.
Source: Peer-reviewed clinical trial in The Lancet HIV.
What This Tells Us About Evidence Quality
The strongest tesamorelin evidence is tied to one specific population (adults with HIV-associated lipodystrophy). The liver and cognitive studies are interesting but preliminary, and none support extending tesamorelin to general wellness use.
Frequently Asked Questions
Were tesamorelin trials placebo-controlled?
Yes — the pivotal trials were randomized, double-blind, and placebo-controlled.
Do the trials show tesamorelin works for general weight loss?
No. Overall body weight changed little, and the studies were in a specific HIV-associated condition.
The Bottom Line
The tesamorelin clinical trials are relatively robust for one specific condition, but thinner and more preliminary everywhere else — which is the honest way to read tesamorelin clinical trials.
This article is for general educational purposes only. It is not medical advice and should not be used to diagnose, treat, or make decisions about any health condition or medication.
Primary Sources
- FDA prescribing information for EGRIFTA WR
- The Lancet HIV tesamorelin/liver-fat trial
Wellness should feel clear, personal, and supported.
Start with education, ask the right questions, and take the next step with confidence.
Get in touch →